Searchable abstracts of presentations at key conferences in endocrinology

ea0041ep69 | Adrenal cortex (to include Cushing's) | ECE2016

Hyperparathyroidism healing in patients treated for hyperaldosteronism: three cases

Blasco Lourdes Garcia , Garcia Juan Carlos Ferrer , Torrens Mercedes Tolosa , Revert Pablo Sanz , Alacid Cristian Marco , Juan Carlos Sanchez

Introduction: Hyperaldosteronism usually presents with hypertension and hypokalemia; however, there is recent evidence of a relationship with the parathyroid hormone. There are different theories to try to explain this relationship. Hyperaldosteronism treatment is medical or surgical depending upon etiology. We present three cases in which treatment solely for hyperaldosteronism also cured hyperparathyroidism.Materials and methods: We report three patien...

ea0014p476 | (1) | ECE2007

Central hypothyrodism and dyslipidemia induced by bexarotene in patients with cutaneous T-cell lymphoma

Sánchez-Juan Carlos , Gamón Elena Roche , Fabra Xelo García , Miquel Victor Alegre de , Galera Raquel Albalat , García Juan-Carlos Ferrer

Background and aims: Bexarotene is the first retinoid receptor X (RXR)-selective agonist approved for cutaneous T-cell lymphoma in patients resistant to at least one previus systemic treatment. However, it produces often two endocrine-metabolic alterations: central hypothyroidism and dyslipidemia. We assessed, in a group of patients with Mycosis Fungoide or Sezary syndrome treated with bexarotene, the endocrine-metabolic side effects.Patients and methods...

ea0056p606 | Obesity | ECE2018

Differences in percentage of weight loss and secondary effects after one and two months of treatment with liraglutide versus naltrexone/bupropion

Voltas Arribas Beatriz , Juan Carlos Sanchez , Garcia Juan Carlos Ferrer , Fullana Ana Artero , Revert Pablo Sanz , Alacid Cristian Marco , Merseguer Mario Lopez

Introduction: Obesity is one of the most prevalent health problems in our society. The marketing of Liraglutide and the Naltrexone/Bupropion combination has been given the green light.Objectives: To analyze the differences in a series of 19 patients assigned to treatment with Liraglutide or Naltrexone/Bupropion.Material and methods: A descriptive analysis was carried out using Stata. 19 patients were included, 9 were treated with L...